Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AVROBIO, Inc. stock logo
AVRO
AVROBIO
$9.98
$0.88
$1.65
$62.85M1.23269,831 shs206,800 shs
CEL-SCI Co. stock logo
CVM
CEL-SCI
$10.43
+12.0%
$6.43
$1.98
$39.30
$71.78M0.54373,970 shs514,864 shs
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
$1.80
-2.2%
$1.78
$1.12
$4.20
$134.13M0.91188,350 shs71,026 shs
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$1.55
$1.52
$0.90
$3.10
$123.59M-0.23830,486 shs672,081 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AVROBIO, Inc. stock logo
AVRO
AVROBIO
0.00%0.00%0.00%0.00%0.00%
CEL-SCI Co. stock logo
CVM
CEL-SCI
0.00%+9.56%+10.37%+320.56%-67.81%
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
0.00%-4.76%+18.42%-12.20%+28.57%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
0.00%-6.63%+6.90%-1.90%+64.16%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AVROBIO, Inc. stock logo
AVRO
AVROBIO
N/AN/AN/AN/AN/AN/AN/AN/A
CEL-SCI Co. stock logo
CVM
CEL-SCI
0.4672 of 5 stars
0.04.00.00.00.01.70.6
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
2.0096 of 5 stars
3.32.00.00.03.70.00.6
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
3.2226 of 5 stars
3.52.00.00.03.21.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AVROBIO, Inc. stock logo
AVRO
AVROBIO
0.00
N/AN/AN/A
CEL-SCI Co. stock logo
CVM
CEL-SCI
0.00
N/AN/AN/A
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
2.50
Moderate Buy$6.50261.11% Upside
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
3.00
Buy$15.00867.74% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AVROBIO, Inc. stock logo
AVRO
AVROBIO
N/AN/AN/AN/A$2.13 per shareN/A
CEL-SCI Co. stock logo
CVM
CEL-SCI
N/AN/AN/AN/A$0.15 per shareN/A
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
N/AN/AN/AN/A$1.78 per shareN/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$61.95M1.99$0.09 per share17.80$0.47 per share3.30
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AVROBIO, Inc. stock logo
AVRO
AVROBIO
$12.16M$0.692.03N/AN/AN/A-50.52%-47.13%N/A
CEL-SCI Co. stock logo
CVM
CEL-SCI
-$26.92M-$9.77N/AN/AN/AN/A-238.05%-104.65%N/A
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$8.31M$0.07N/A5.00N/A-21.03%-30.89%-11.74%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AVROBIO, Inc. stock logo
AVRO
AVROBIO
N/AN/AN/AN/AN/A
CEL-SCI Co. stock logo
CVM
CEL-SCI
N/AN/AN/AN/AN/A
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
N/AN/AN/AN/AN/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AVROBIO, Inc. stock logo
AVRO
AVROBIO
N/A
26.17
26.17
CEL-SCI Co. stock logo
CVM
CEL-SCI
0.66
1.07
1.09
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
N/A
0.85
0.85
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/A
1.98
1.27

Institutional Ownership

CompanyInstitutional Ownership
AVROBIO, Inc. stock logo
AVRO
AVROBIO
62.63%
CEL-SCI Co. stock logo
CVM
CEL-SCI
12.08%
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
3.81%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
16.53%

Insider Ownership

CompanyInsider Ownership
AVROBIO, Inc. stock logo
AVRO
AVROBIO
9.20%
CEL-SCI Co. stock logo
CVM
CEL-SCI
9.93%
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
7.30%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
6.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
AVROBIO, Inc. stock logo
AVRO
AVROBIO
1344.89 million40.76 millionOptionable
CEL-SCI Co. stock logo
CVM
CEL-SCI
436.88 million64.67 millionOptionable
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
674.52 million66.18 millionNot Optionable
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
20079.73 million69.00 millionOptionable

Recent News About These Companies

What is HC Wainwright's Estimate for PLX FY2025 Earnings?
What is HC Wainwright's Forecast for PLX Q3 Earnings?
PLX: New CFO to Take the Reins
Protalix BioTherapeutics lifts revenue on strong Elfabrio demand
Protalix Lawsuit Dismissed After Bylaws Amendment
Protalix BioTherapeutics Names SVP and CFO

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVROBIO stock logo

AVROBIO NASDAQ:AVRO

AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

CEL-SCI stock logo

CEL-SCI NYSE:CVM

$10.43 +1.12 (+12.03%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$10.46 +0.03 (+0.25%)
As of 08/29/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

Inhibikase Therapeutics stock logo

Inhibikase Therapeutics NYSE:IKT

$1.80 -0.04 (-2.17%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$1.80 0.00 (0.00%)
As of 08/29/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Protalix BioTherapeutics stock logo

Protalix BioTherapeutics NYSE:PLX

$1.55 0.00 (0.00%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$1.58 +0.02 (+1.61%)
As of 08/29/2025 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.